Pay in 4 interest-free payments of $6.28 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Not recommended for use with warfarin
The triple therapy of metformin, a DPP-4 inhibitor and a SGLT-2 inhibitor has a very low treatment related hypoglycaemia risk, leads to a further, almost additive reduction of glycaemic parameters, a body weight loss in the same range as with a mono- or dual therapy with a SGLT-2 inhibitor and also to the expected SGLT-2 inhibitor induced reduction of blood pressure
Consult with our healthcare team to determine if its right for you
This isnt one-on-one behavior coaching
sit less
US$ 27.06
US$ 24.67
US$ 24.11
US$ 29.66
US$ 23.45
US$ 20.54
US$ 23.88
US$ 21.72
US$ 28.74
